WGU D027 FINAL EXAM COMPLETE STUDY GUIDE
2026/2027 | Advanced Pathopharmacological Foundations |
Questions & Verified Answers 100% Correct | Pass
Guaranteed - A+ Graded
Principles of Pharmacology: Pharmacokinetics, Pharmacodynamics, ADME,
Receptors, and Adverse Drug Reactions
Q1: A 68-year-old patient with heart failure is prescribed digoxin 0.25 mg daily. The
nurse practitioner reviews the patient's laboratory results and notes a serum potassium
level of 2.8 mEq/L. What is the most appropriate action?
A. Administer the digoxin as prescribed and recheck potassium in one week
B. Hold the digoxin and administer potassium supplements immediately
C. Hold the digoxin and administer potassium supplements immediately [CORRECT]
D. Reduce the digoxin dose by 50% and continue therapy
Correct Answer: C
Rationale: Hypokalemia increases the risk of digoxin toxicity because low potassium
levels enhance the binding of digoxin to cardiac tissue. The therapeutic index for
,digoxin is narrow (0.5-0.9 ng/mL for heart failure; 0.8-1.2 ng/mL for atrial fibrillation).
With a potassium level of 2.8 mEq/L (normal 3.5-5.0 mEq/L), the nurse practitioner
must hold the digoxin and replete potassium to prevent potentially fatal arrhythmias.
Option A is dangerous due to toxicity risk; Option B incorrectly suggests immediate
administration without holding the drug; Option D is insufficient as the potassium deficit
must be corrected first.
Q2: A patient with chronic kidney disease (CKD) stage 4 is prescribed gabapentin for
neuropathic pain. Which pharmacokinetic parameter requires the most significant
adjustment in this patient?
A. Absorption rate will be significantly delayed due to gastric pH changes
B. Distribution volume decreases, requiring higher loading doses
C. Renal clearance is reduced, requiring dose adjustment [CORRECT]
D. Protein binding increases, necessitating free drug level monitoring
Correct Answer: C
Rationale: Gabapentin is primarily eliminated unchanged by the kidneys. In CKD stage 4
(GFR 15-29 mL/min), renal clearance is significantly impaired, leading to drug
accumulation and increased risk of adverse effects. The dose must be adjusted based
on creatinine clearance. Option A is incorrect because absorption isn't significantly
,affected by CKD; Option B is wrong because volume of distribution isn't the primary
concern; Option D is incorrect as gabapentin has minimal protein binding.
Q3: Which cytochrome P450 enzyme is responsible for metabolizing approximately 50%
of all clinically used drugs?
A. CYP2D6
B. CYP3A4 [CORRECT]
C. CYP2C9
D. CYP1A2
Correct Answer: B
Rationale: CYP3A4 is the most abundant cytochrome P450 enzyme in the liver and
metabolizes approximately 50% of clinically used drugs, including many statins, calcium
channel blockers, and immunosuppressants. It is also involved in numerous drug-drug
interactions. CYP2D6 (Option A) metabolizes about 25% of drugs; CYP2C9 (Option C)
and CYP1A2 (Option D) metabolize smaller percentages.
Q4: A patient taking warfarin 5 mg daily requires initiation of fluconazole for a fungal
infection. What is the primary concern regarding this drug combination?
, A. Fluconazole inhibits CYP2C9, increasing warfarin levels and bleeding risk [CORRECT]
B. Fluconazole induces CYP3A4, decreasing warfarin effectiveness
C. Fluconazole inhibits CYP3A4, increasing warfarin levels
D. Fluconazole competes for protein binding, displacing warfarin
Correct Answer: A
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme responsible
for metabolizing warfarin (an S-warfarin substrate). Inhibition of this enzyme increases
warfarin plasma levels and significantly elevates INR and bleeding risk. Option B is
incorrect because fluconazole inhibits rather than induces; Option C identifies the wrong
enzyme; Option D describes a different mechanism not primarily responsible for the
fluconazole-warfarin interaction.
Q5: Which statement accurately describes first-order versus zero-order kinetics?
A. First-order kinetics: Constant amount of drug eliminated per unit time; zero-order:
Constant fraction eliminated
B. First-order kinetics: Constant fraction eliminated per unit time; zero-order: Constant
amount eliminated [CORRECT]
C. Both follow first-order kinetics at therapeutic doses
2026/2027 | Advanced Pathopharmacological Foundations |
Questions & Verified Answers 100% Correct | Pass
Guaranteed - A+ Graded
Principles of Pharmacology: Pharmacokinetics, Pharmacodynamics, ADME,
Receptors, and Adverse Drug Reactions
Q1: A 68-year-old patient with heart failure is prescribed digoxin 0.25 mg daily. The
nurse practitioner reviews the patient's laboratory results and notes a serum potassium
level of 2.8 mEq/L. What is the most appropriate action?
A. Administer the digoxin as prescribed and recheck potassium in one week
B. Hold the digoxin and administer potassium supplements immediately
C. Hold the digoxin and administer potassium supplements immediately [CORRECT]
D. Reduce the digoxin dose by 50% and continue therapy
Correct Answer: C
Rationale: Hypokalemia increases the risk of digoxin toxicity because low potassium
levels enhance the binding of digoxin to cardiac tissue. The therapeutic index for
,digoxin is narrow (0.5-0.9 ng/mL for heart failure; 0.8-1.2 ng/mL for atrial fibrillation).
With a potassium level of 2.8 mEq/L (normal 3.5-5.0 mEq/L), the nurse practitioner
must hold the digoxin and replete potassium to prevent potentially fatal arrhythmias.
Option A is dangerous due to toxicity risk; Option B incorrectly suggests immediate
administration without holding the drug; Option D is insufficient as the potassium deficit
must be corrected first.
Q2: A patient with chronic kidney disease (CKD) stage 4 is prescribed gabapentin for
neuropathic pain. Which pharmacokinetic parameter requires the most significant
adjustment in this patient?
A. Absorption rate will be significantly delayed due to gastric pH changes
B. Distribution volume decreases, requiring higher loading doses
C. Renal clearance is reduced, requiring dose adjustment [CORRECT]
D. Protein binding increases, necessitating free drug level monitoring
Correct Answer: C
Rationale: Gabapentin is primarily eliminated unchanged by the kidneys. In CKD stage 4
(GFR 15-29 mL/min), renal clearance is significantly impaired, leading to drug
accumulation and increased risk of adverse effects. The dose must be adjusted based
on creatinine clearance. Option A is incorrect because absorption isn't significantly
,affected by CKD; Option B is wrong because volume of distribution isn't the primary
concern; Option D is incorrect as gabapentin has minimal protein binding.
Q3: Which cytochrome P450 enzyme is responsible for metabolizing approximately 50%
of all clinically used drugs?
A. CYP2D6
B. CYP3A4 [CORRECT]
C. CYP2C9
D. CYP1A2
Correct Answer: B
Rationale: CYP3A4 is the most abundant cytochrome P450 enzyme in the liver and
metabolizes approximately 50% of clinically used drugs, including many statins, calcium
channel blockers, and immunosuppressants. It is also involved in numerous drug-drug
interactions. CYP2D6 (Option A) metabolizes about 25% of drugs; CYP2C9 (Option C)
and CYP1A2 (Option D) metabolize smaller percentages.
Q4: A patient taking warfarin 5 mg daily requires initiation of fluconazole for a fungal
infection. What is the primary concern regarding this drug combination?
, A. Fluconazole inhibits CYP2C9, increasing warfarin levels and bleeding risk [CORRECT]
B. Fluconazole induces CYP3A4, decreasing warfarin effectiveness
C. Fluconazole inhibits CYP3A4, increasing warfarin levels
D. Fluconazole competes for protein binding, displacing warfarin
Correct Answer: A
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme responsible
for metabolizing warfarin (an S-warfarin substrate). Inhibition of this enzyme increases
warfarin plasma levels and significantly elevates INR and bleeding risk. Option B is
incorrect because fluconazole inhibits rather than induces; Option C identifies the wrong
enzyme; Option D describes a different mechanism not primarily responsible for the
fluconazole-warfarin interaction.
Q5: Which statement accurately describes first-order versus zero-order kinetics?
A. First-order kinetics: Constant amount of drug eliminated per unit time; zero-order:
Constant fraction eliminated
B. First-order kinetics: Constant fraction eliminated per unit time; zero-order: Constant
amount eliminated [CORRECT]
C. Both follow first-order kinetics at therapeutic doses
